Health
Affinity’s COVID-19 antibodies ready for manufacture for clinical trials – BSA bureau
The study offers a roadmap for speeding development of Monoclonal Antibodies for other diseases; Techniques applied to COVID-19 studies completed Phase 1 Trial
The study offers a roadmap for speeding development of Monoclonal Antibodies for other diseases; Techniques applied to COVID-19 studies completed Phase 1 Trial
Tychan, a Singapore-based clinical-stage biotechnology company focused on developing life-saving treatments through disruptive technologies, announced on 30 July 2020 a publication in New England Journal of Medicine (NEJM) demonstrating the safety and efficacy for TY014, a novel monoclonal antibody candidate treatment for yellow fever (Y…
-
General23 hours agoWe’ve all talked about potential economic consequences for Australia of Trump’s policies. Now they’re happening
-
Noosa News18 hours agoMoreton Bay oyster farm survives cyclone with help of wave wall innovation
-
Noosa News20 hours agoHelicopter pilots saving lives, providing food and fodder in flooded outback Queensland
-
Noosa News23 hours ago’Lethal new opioids’ prompt Wide Bay pill testing call